Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

International Journal of Clinical Oncology
Rurina WatanukiYuko Kitagawa

Abstract

In adjuvant settings of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, anthracycline-based chemotherapy followed by taxane and trastuzumab is a standard regimen. Recent studies have reported the use of anthracycline-free adjuvant chemotherapy in selected HER2-positive breast cancer patients. We conducted a single-center retrospective study to identify the characteristics of HER2-positive breast cancer patients for whom anthracyclines can be safely omitted. A total of 238 women were diagnosed with HER2-positive breast cancer and treated with neoadjuvant and/or adjuvant chemotherapy between January 1, 2008 and December 31, 2015 at Keio University Hospital. They were divided in two cohorts: an "anthracycline" cohort of 112 anthracycline-treated women and a "no anthracycline" cohort of 126 anthracycline-untreated women. Survival outcomes were estimated by Kaplan-Meier method. The 3-year disease-free survival rates in the no-anthracycline and anthracycline cohorts were 91.3% and 93.1%, respectively (P = 0.692). After using a statistical method with inverse probability of treatment weighting to minimize the selection bias, no significant differences were observed between the two cohorts (adjusted hazard ratio...Continue Reading

References

Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R SeshadriP Kitchen
May 26, 2004·Computer Methods and Programs in Biomedicine·Stephen R Cole, Miguel A Hernán
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Jun 23, 2006·Journal of Epidemiology and Community Health·Miguel A Hernán, James M Robins
Jun 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick G Morris, Clifford A Hudis
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinClifford A Hudis
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon H GiordanoJames S Goodwin
Sep 17, 2014·Journal of the National Cancer Institute·Aiko NagayamaYuko Kitagawa
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer
Nov 12, 2015·Breast Care·Amelie SchrammJens Huober
Feb 7, 2017·Reviews on Recent Clinical Trials·Rachel Wuerstlein, Nadia Harbeck
Jun 6, 2017·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN APHINITY Steering Committee and Investigators
Jul 16, 2017·Breast Cancer Research and Treatment·Anthony F YuChau T Dang
Nov 12, 2017·Cancer Treatment Reviews·Ayako NakashojiYuko Kitagawa

❮ Previous
Next ❯

Citations

Dec 6, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Ali Raza KhakiVinay Prasad
Oct 23, 2019·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Sep 13, 2020·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.